Published in Heart on March 01, 2003
Simulations of congenital septal defect closure and reactivity testing in patient-specific models of the pediatric pulmonary vasculature: A 3D numerical study with fluid-structure interaction. J Biomech Eng (2006) 1.03
Impact of residual stretch and remodeling on collagen engagement in healthy and pulmonary hypertensive calf pulmonary arteries at physiological pressures. Ann Biomed Eng (2012) 1.02
Wall shear stress is decreased in the pulmonary arteries of patients with pulmonary arterial hypertension: An image-based, computational fluid dynamics study. Pulm Circ (2012) 0.98
In vivo and in vitro measurements of pulmonary arterial stiffness: A brief review. Pulm Circ (2012) 0.97
Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee. Pulm Circ (2013) 0.94
Abnormal pulmonary artery stiffness in pulmonary arterial hypertension: in vivo study with intravascular ultrasound. PLoS One (2012) 0.88
Mechanics and Function of the Pulmonary Vasculature: Implications for Pulmonary Vascular Disease and Right Ventricular Function. Compr Physiol (2012) 0.87
Impact of pulmonary vascular stiffness and vasodilator treatment in pediatric pulmonary hypertension: 21 patient-specific fluid-structure interaction studies. Comput Methods Programs Biomed (2011) 0.86
The role of pulmonary arterial stiffness in COPD. Respir Med (2015) 0.84
Application of a microstructural constitutive model of the pulmonary artery to patient-specific studies: validation and effect of orthotropy. J Biomech Eng (2007) 0.84
Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension. J Biomech Eng (2013) 0.82
Hemodynamic assessment of pulmonary hypertension. World J Cardiol (2011) 0.81
Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. JCI Insight (2016) 0.81
Impairment of pulmonary vascular reserve and right ventricular systolic reserve in pulmonary arterial hypertension. BMC Pulm Med (2014) 0.81
New concepts in the invasive and non invasive evaluation of remodelling of the right ventricle and pulmonary vasculature in pulmonary arterial hypertension. Open Respir Med J (2009) 0.78
In vivo assessment of pulmonary arterial wall fibrosis by intravascular optical coherence tomography in pulmonary arterial hypertension: a new prognostic marker of adverse clinical follow-up. Open Respir Med J (2013) 0.78
Validation of an arterial constitutive model accounting for collagen content and crosslinking. Acta Biomater (2015) 0.77
Pulmonary vascular stiffness: measurement, modeling, and implications in normal and hypertensive pulmonary circulations. Compr Physiol (2011) 0.76
Assessment of proximal pulmonary arterial stiffness using magnetic resonance imaging: effects of technique, age and exercise. BMJ Open Respir Res (2016) 0.75
Aerosolized polymerized type I collagen reduces airway inflammation and remodelling in a guinea pig model of allergic asthma. Lung (2009) 0.75
Arterial Stiffness Induces Remodeling Phenotypes in Pulmonary Artery Smooth Muscle Cells via YAP/TAZ-Mediated Repression of Cyclooxygenase-2. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 211.50
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80
Primary pulmonary hypertension. N Engl J Med (1997) 4.97
Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med (1998) 4.01
Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation (1989) 2.16
A simple method for the representative sampling of lungs of diverse size. Thorax (1979) 1.63
Pharmacodynamic profile of prostacyclin. Am J Cardiol (1995) 1.51
Relationship between haemodynamics and morphology in pulmonary hypertension. A quantitative intravascular ultrasound study. Eur Heart J (1997) 1.49
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol (1997) 1.46
Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart (1998) 1.24
Pressure and flow generated by the left ventricle against different impedances. Circ Res (1973) 1.20
Pulmonary artery compliance: its role in right ventricular-arterial coupling. Cardiovasc Res (1992) 1.17
Intracardiac, intravascular, two-dimensional, high-frequency ultrasound imaging of pulmonary artery and its branches in humans and animals. Circulation (1990) 1.12
Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation (2000) 1.10
Vascular mechanics for the cardiologist. J Am Coll Cardiol (1994) 1.08
Evaluation of pulmonary artery histopathologic findings in congenital heart disease: an in vitro study using intravascular ultrasound imaging. J Am Coll Cardiol (1995) 0.93
Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Chest (2001) 0.92
Effects of arterial distensibility on left ventricular ejection in the depressed contractile state. Cardiovasc Res (1993) 0.87
Blood flow distribution in the lung. Chest (1998) 0.84
Intravascular ultrasound in diagnosis of acute pulmonary embolism. Lancet (1991) 0.83
Intravascular ultrasonic characteristics and vasoreactivity of the pulmonary vasculature in children with pulmonary hypertension. Am J Cardiol (1998) 0.83
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart (1997) 0.82
Catheter-based intravascular ultrasound imaging of chronic thromboembolic pulmonary disease. Am J Cardiol (1991) 0.81
Evaluation of the pulmonary vasculature and dynamics with intravascular ultrasound imaging in children and infants. Pediatr Res (1995) 0.80
Direct in vivo evaluation of pulmonary arterial pathology in chronic congestive heart failure with catheter-based intravascular ultrasound imaging. Am J Cardiol (1993) 0.78
Nucleotide sequence heterogeneity of an RNA phage population. Cell (1978) 5.55
Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proc Natl Acad Sci U S A (1992) 4.22
Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev (2006) 4.13
The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review. Gene (1985) 3.42
Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol (1990) 3.11
Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology (1983) 3.04
The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene (1976) 2.77
Long-term follow-up of idiopathic chronic pericardial effusion. N Engl J Med (1999) 2.71
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol (1995) 2.68
Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci U S A (1995) 2.60
Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses. J Virol (1993) 2.55
Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. Gene (1980) 2.44
Genetic lesions associated with Muller's ratchet in an RNA virus. J Mol Biol (1996) 2.41
Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation (1999) 2.38
Lack of evolutionary stasis during alternating replication of an arbovirus in insect and mammalian cells. J Mol Biol (1999) 2.28
Virus mutation frequencies can be greatly underestimated by monoclonal antibody neutralization of virions. J Virol (1989) 2.27
Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol (2000) 2.26
Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene (1992) 2.20
Clinical clues to the causes of large pericardial effusions. Am J Med (2000) 2.20
Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. J Virol (1995) 2.18
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Evolution of cell recognition by viruses. Science (2001) 2.14
Diagnostic accuracy of technetium-99m-MIBI myocardial SPECT in women and men. J Nucl Med (1998) 2.12
Subclonal components of consensus fitness in an RNA virus clone. J Virol (1994) 2.09
RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis (1994) 2.08
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene (2006) 2.07
The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities. Virology (1993) 2.05
Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet. J Mol Biol (1999) 2.00
Genetic variability of Hong Kong (H3N2) influenza viruses: spontaneous mutations and their location in the viral genome. Gene (1980) 1.95
Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle. J Virol (1988) 1.92
Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. J Virol (1988) 1.90
Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies. J Virol (1991) 1.89
Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol (2001) 1.86
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol (1999) 1.85
Establishment of cell lines persistently infected with foot-and-mouth disease virus. Virology (1985) 1.84
Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells. J Virol (1995) 1.84
Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol (1985) 1.83
The red queen reigns in the kingdom of RNA viruses. Proc Natl Acad Sci U S A (1994) 1.83
Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol (1996) 1.83
Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology (2010) 1.83
The structure and antigenicity of a type C foot-and-mouth disease virus. Structure (1994) 1.82
Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. Cardiovasc Res (1993) 1.82
Purulent pericarditis: review of a 20-year experience in a general hospital. J Am Coll Cardiol (1993) 1.79
Should pericardial drainage be performed routinely in patients who have a large pericardial effusion without tamponade? Am J Med (1998) 1.75
RNA virus evolution and the control of viral disease. Prog Drug Res (1989) 1.74
In vitro site-directed mutagenesis: generation and properties of an infectious extracistronic mutant of bacteriophage Qbeta. Gene (1976) 1.72
Evolution of the capsid protein genes of foot-and-mouth disease virus: antigenic variation without accumulation of amino acid substitutions over six decades. J Virol (1992) 1.72
Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1989) 1.71
Memory in viral quasispecies. J Virol (2000) 1.70
Long-term complications of native valve infective endocarditis in non-addicts. A 15-year follow-up study. Ann Intern Med (1992) 1.67
Evolution of the nucleotide sequence of influenza virus RNA segment 7 during drift of the H3N2 subtype. Gene (1983) 1.64
Comparative effects of morphine, meperidine and pentazocine on cardiocirculatory dynamics in patients with acute myocardial infarction. Am J Med (1976) 1.61
Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci U S A (2002) 1.60
Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res (2001) 1.60
Exponential fitness gains of RNA virus populations are limited by bottleneck effects. J Virol (1999) 1.60
Transient cardiac constriction: an unrecognized pattern of evolution in effusive acute idiopathic pericarditis. Am J Cardiol (1987) 1.60
A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J Gen Virol (1990) 1.57
Origin and evolution of viruses. Virus Genes (1998) 1.56
Left ventricular free wall rupture: clinical presentation and management. Heart (2000) 1.53
Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern Med (1999) 1.53
Fixation of mutations in the viral genome during an outbreak of foot-and-mouth disease: heterogeneity and rate variations. Gene (1986) 1.53
Flow cytometry and the study of central nervous disease in patients with acute leukaemia. Br J Haematol (2001) 1.52
Multiple virulence determinants of foot-and-mouth disease virus in cell culture. J Virol (1998) 1.52
Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation (1998) 1.51
Results of a case-detection programme for alpha1-antitrypsin deficiency in COPD patients. Eur Respir J (2005) 1.51
A single nucleotide substitution in the internal ribosome entry site of foot-and-mouth disease virus leads to enhanced cap-independent translation in vivo. J Virol (1993) 1.50
Foot-and-mouth disease virus lacking the VP1 G-H loop: the mutant spectrum uncovers interactions among antigenic sites for fitness gain. Virology (2001) 1.50
Immobilized dimers of N-cadherin-Fc chimera mimic cadherin-mediated cell contact formation: contribution of both outside-in and inside-out signals. J Cell Sci (2000) 1.49
Effects of whole-body vibration and resistance training on knee extensors muscular performance. Eur J Appl Physiol (2011) 1.47
Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest. J Am Coll Cardiol (2000) 1.47
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol (2012) 1.46
Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J Virol (1997) 1.45
Pulsatile hemodynamics in congestive heart failure. Hypertension (2001) 1.44
Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. EMBO J (1996) 1.44
The epithelial cell response to rotavirus infection. J Immunol (1999) 1.44
Extensive antigenic heterogeneity of foot-and-mouth disease virus of serotype C. Virology (1988) 1.42
Prognostic assessment of uncomplicated first myocardial infarction by exercise echocardiography and Tc-99m tetrofosmin gated SPECT. J Nucl Cardiol (2001) 1.42
Tuberculous pericarditis: ten year experience with a prospective protocol for diagnosis and treatment. J Am Coll Cardiol (1988) 1.41
[The usefulness of Doppler echocardiography in the preoperative assessment of valvulopathies. A comparison with the hemodynamic and surgical findings]. Rev Esp Cardiol (1993) 1.40
Variations in diagnostic yield of head-up tilt test and electrophysiology in groups of patients with syncope of unknown origin. Eur Heart J (2001) 1.40
Modifications of the 5' untranslated region of foot-and-mouth disease virus after prolonged persistence in cell culture. Virus Res (1992) 1.40
Many-trillionfold amplification of single RNA virus particles fails to overcome the Muller's ratchet effect. J Virol (1993) 1.40
Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J (2000) 1.40
Medical management of selected patients with left ventricular free wall rupture during acute myocardial infarction. J Am Coll Cardiol (1997) 1.39
[Nonspecific interstitial pneumonia: epidemiologic and clinical characteristics]. Med Clin (Barc) (2006) 1.39
[Idiopathic thrombocytopenic purpura in 5 members of a family]. Sangre (Barc) (1994) 1.39
Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart (2007) 1.38
Uncomplicated first myocardial infarction: strategy for comprehensive prognostic studies. J Am Coll Cardiol (1991) 1.38
Evolution subverting essentiality: dispensability of the cell attachment Arg-Gly-Asp motif in multiply passaged foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1997) 1.37
Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation (1999) 1.36
A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol (1997) 1.36
Unique amino acid substitutions in the capsid proteins of foot-and-mouth disease virus from a persistent infection in cell culture. J Virol (1990) 1.35
Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition. J Biol Chem (1996) 1.33
Correlation between clinical and Doppler echocardiographic findings in patients with moderate and large pericardial effusion: implications for the diagnosis of cardiac tamponade. Am Heart J (1999) 1.32